Organogenesis Holdings Inc
NASDAQ:ORGO
Organogenesis Holdings Inc
Operating Income
Organogenesis Holdings Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
Operating Income
$12.7m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
See Also
What is Organogenesis Holdings Inc's Operating Income?
Operating Income
12.7m
USD
Based on the financial report for Mar 31, 2024, Organogenesis Holdings Inc's Operating Income amounts to 12.7m USD.
What is Organogenesis Holdings Inc's Operating Income growth rate?
Operating Income CAGR 3Y
-38%
Over the last year, the Operating Income growth was -31%. The average annual Operating Income growth rates for Organogenesis Holdings Inc have been -38% over the past three years .